Alert on the lack of clinical effective therapeutic solutions to treat critically ill patients in Europe, mainly in hospitals where multidrug-resistant (MDR) bacteria are primarily found. This si- lent pandemic is an immediate consequence of a reduction in the commitment and investments in the discovery and development of new antibiotics (WHO, 2023), as well as the best example of the purported “Post-Antibiotic Era”, as highlighted even in non-specialized media.
Solving the antibacterial resistance in Europe: The multipronged approach of the COST Action CA21145 EURESTOP / Seguin-Devaux C.; Mestrovic T.; Arts J.J.; Sen Karaman D.; Nativi C.; Reichmann D.; Sahariah P.; Smani Y.; Rijo P.; Mori M.. - In: DRUG RESISTANCE UPDATES. - ISSN 1368-7646. - STAMPA. - 74:(2024), pp. 101069.101069-101069.101071. [10.1016/j.drup.2024.101069]
Solving the antibacterial resistance in Europe: The multipronged approach of the COST Action CA21145 EURESTOP
Nativi C.Conceptualization
;
2024
Abstract
Alert on the lack of clinical effective therapeutic solutions to treat critically ill patients in Europe, mainly in hospitals where multidrug-resistant (MDR) bacteria are primarily found. This si- lent pandemic is an immediate consequence of a reduction in the commitment and investments in the discovery and development of new antibiotics (WHO, 2023), as well as the best example of the purported “Post-Antibiotic Era”, as highlighted even in non-specialized media.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
